Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |
PMID | |
Authors | Govind Ragupathi, Xiaohong Wu, Philip Livingston, Wolfgang Scholz, Christine Kearns and Paul Maffuid |
Title | Abstract A73: Antitumor activity of MVT-5873, a monoclonal antibody targeting sialyl Lewisa, alone and in combination with gemcitabine/nab-paclitaxel in a BxPC3 human pancreatic cancer xenograft model |
Journal | Cancer Research |
Vol | |
Issue | |
Date | |
URL | http://cancerres.aacrjournals.org/content/76/24_Supplement/A73.short |
Abstract Text | Cancer Res 2016;76(24 Suppl):Abstract nr A73 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MVT-5873 | HuMab 5B1|HuMab-5B1 | MVT-5873 (HuMab-5B1) is an IgG1 antibody that binds to the sialyl Lewis A epitope of CA19-9, which may result in antitumor activity including tumor growth inhibition (Cancer Res 2016;76(24 Suppl):Abstract nr A73, PMID: 32399263). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | pancreatic cancer | not applicable | Gemcitabine + MVT-5873 + Nab-paclitaxel | Preclinical - Cell line xenograft | Actionable | In a preclinical study, MVT-5873 enhanced efficacy of the combination therapy, Gemzar (gemcitabine) and Abraxane (nab-paclitaxel), in pancreatic xenograft models, demonstrating increased inhibition of tumor growth and greater reduction of tumor volume when compared to single agents (Cancer Res 2016;76(24 Suppl):Abstract nr A73). | detail... |
Unknown unknown | pancreatic cancer | not applicable | MVT-5873 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, a pancreatic xenograft model demonstrated reduced tumor volume and tumor growth inhibition when treated with MVT-5873 (Cancer Res 2016;76(24 Suppl):Abstract nr A73). | detail... |